Special Issue "Gene Therapy Strategies for HIV/AIDS"

A special issue of Biomedicines (ISSN 2227-9059).

Deadline for manuscript submissions: closed (30 January 2016).

Special Issue Editor

Dr. Grant Trobridge
Website
Guest Editor
Department of Pharmaceutical Sciences, Washington State University, Pullman, WA 99164, USA
Interests: hematopoietic stem cell gene therapy; foamy retroviral vectors; vector-mediated genotoxicity; retroviral mutagenesis screens for cancer drivers

Special Issue Information

Dear Colleagues,

This Special Issue “Gene Therapy Strategies for HIV/AIDS” will focus on novel approaches to treat HIV/AIDS using gene transfer.

The cure of the “Berlin patient” by transplantation of allogeneic hematopoietic stem cells has provided a proof of principle that HIV/AIDS can be treated using genetically resistant stem cells. This has led to preclinical and clinical studies exploring numerous approaches to create genetically modified hematopoietic stem cells and T cells that resist HIV infection. In addition, means to deliver transgenes encoding broadly neutralizing antibodies or antibody-fusions to muscle cells have shown great promise.

This issue will focus on novel approaches to HIV gene therapy, vector efficacy and safety, preclinical models and immunogenicity, and translation to the clinic.

Dr. Grant Trobridge
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • HIV gene therapy
  • viral vector
  • stem cell gene therapy
  • gene targeting
  • preclinical models

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Open AccessReview
Prospects for Foamy Viral Vector Anti-HIV Gene Therapy
Biomedicines 2016, 4(2), 8; https://doi.org/10.3390/biomedicines4020008 - 29 Mar 2016
Cited by 2
Abstract
Stem cell gene therapy approaches for Human Immunodeficiency Virus (HIV) infection have been explored in clinical trials and several anti-HIV genes delivered by retroviral vectors were shown to block HIV replication. However, gammaretroviral and lentiviral based retroviral vectors have limitations for delivery of [...] Read more.
Stem cell gene therapy approaches for Human Immunodeficiency Virus (HIV) infection have been explored in clinical trials and several anti-HIV genes delivered by retroviral vectors were shown to block HIV replication. However, gammaretroviral and lentiviral based retroviral vectors have limitations for delivery of anti-HIV genes into hematopoietic stem cells (HSC). Foamy virus vectors have several advantages including efficient delivery of transgenes into HSC in large animal models, and a potentially safer integration profile. This review focuses on novel anti-HIV transgenes and the potential of foamy virus vectors for HSC gene therapy of HIV. Full article
(This article belongs to the Special Issue Gene Therapy Strategies for HIV/AIDS)
Show Figures

Graphical abstract

Open AccessReview
Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy
Biomedicines 2016, 4(1), 4; https://doi.org/10.3390/biomedicines4010004 - 02 Feb 2016
Cited by 4
Abstract
Retroviral vector gene therapy is a promising approach to treating HIV-1. However, integrated vectors are mutagens with the potential to dysregulate nearby genes and cause severe adverse side effects. Leukemia has already been a documented severe adverse event in gene therapy clinical trials [...] Read more.
Retroviral vector gene therapy is a promising approach to treating HIV-1. However, integrated vectors are mutagens with the potential to dysregulate nearby genes and cause severe adverse side effects. Leukemia has already been a documented severe adverse event in gene therapy clinical trials for the treatment of primary immunodeficiencies. These side effects will need to be reduced or avoided if retroviral vectors are to be used clinically for HIV-1 treatment. The addition of chromatin insulators to retroviral vectors is a potential strategy for reducing adverse side effects. Insulators have already been effectively used in retroviral vectors to reduce genotoxicity in pre-clinical studies. Here, we will review how insulators function, genotoxicity in gene therapy clinical trials, the design of insulated retroviral vectors, promising results from insulated retroviral vector studies, and considerations for the development of insulated retroviral treatment vectors for HIV-1 gene therapy. Full article
(This article belongs to the Special Issue Gene Therapy Strategies for HIV/AIDS)
Show Figures

Graphical abstract

Back to TopTop